Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

1.2K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.2K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a More Equitable Discharge Process.

Hospital pediatrics·2026
Same author

Examining Associations Between Medicaid Policy and Silver Diamine Fluoride Utilization.

Journal of public health dentistry·2026
Same author

A class of deep intronic <i>IGHMBP2</i> variants activate a shared cryptic splice donor, enabling correction of select variants with a single antisense oligonucleotide.

medRxiv : the preprint server for health sciences·2026
Same author

Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder.

Cardiovascular research·2026
Same author

Genomic hallmarks of parasexual reproduction in three hybrid groups of the human pathogen <i>Cryptococcus neoformans</i>.

bioRxiv : the preprint server for biology·2026
Same author

Utility of Follow-Up Surveillance Echocardiograms in Uncomplicated Surgical Closures of Perimembranous Ventricular Septal Defects: A Preliminary Analysis.

Journal of cardiovascular development and disease·2026

Related Experiment Video

Updated: Apr 25, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.3K

Transitioning From Nusinersen to Risdiplam for Spinal Muscular Atrophy in Clinical Practice: A Single-Center

Can Ebru Bekircan-Kurt1, Sharmada Subramanian2, Shannon Chagat3

  • 1Department of Neurology, School of Medicine, Hacettepe University, Ankara, Turkey.

Muscle & Nerve
|January 2, 2025
PubMed
Summary

Transitioning spinal muscular atrophy (SMA) patients from nusinersen to risdiplam showed stable motor function and a favorable safety profile. Cough peak flow improved with risdiplam, indicating potential benefits for respiratory function in SMA patients.

Keywords:
CHOPHFMSENIVnusinersenrisdiplamspinal muscular atrophy

More Related Videos

Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors
07:33

Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors

Published on: May 1, 2019

11.2K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.8K

Related Experiment Videos

Last Updated: Apr 25, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.3K
Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors
07:33

Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors

Published on: May 1, 2019

11.2K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.8K

Area of Science:

  • Neurology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Spinal muscular atrophy (SMA) is a rare genetic disorder affecting motor neurons.
  • Nusinersen and risdiplam are FDA-approved treatments for SMA, but direct comparative efficacy data is limited.
  • Observational studies are crucial to evaluate treatment transitions and long-term outcomes.

Purpose of the Study:

  • To assess the safety and efficacy of transitioning from nusinersen to risdiplam in individuals with SMA.
  • To evaluate changes in motor, pulmonary, and bulbar function after switching treatments.
  • To compare outcomes between patients treated with nusinersen and those who transitioned to risdiplam.

Main Methods:

  • Retrospective study at Nationwide Children's Hospital.
  • Included 44 individuals with SMA (types 1, 2, and 3) previously treated with nusinersen who switched to risdiplam.
  • Assessed motor, pulmonary, and bulbar function pre- and post-treatment initiation (2-year follow-up).

Main Results:

  • Motor function improved with nusinersen, remaining stable after switching to risdiplam.
  • Non-invasive ventilation (NIV) was required in both treatment groups.
  • Cough peak flow significantly improved in the risdiplam group; oral feeding abilities showed improvement in the risdiplam group.
  • Hospitalization rates were similar between groups.

Conclusions:

  • Transitioning from nusinersen to risdiplam appears safe, maintaining motor function stability.
  • While initial gains were seen with nusinersen, risdiplam maintained function and showed improvements in cough and feeding.
  • Spinal fusion surgery impacted outcomes but was slightly less pronounced in the risdiplam group.